Aptevo Therapeutics News, Aptevo Therapeutics Quote, APVO Quote

Aptevo Therapeutics (NQ:APVO) Delayed: 4.57 -0.05 (1.08%)

Prev. Close

$4.62

Today 6M 1Y 5Y

Open

$4.39

52 Wk High

$4.33

52 Wk Low

$1.80

Day High

$4.60

Day Low

$4.21

P/E

N/A

EPS

$0.00

Volume

42,671

Friends, Peers and Foes (?): SXTP FMST (more...)

ALERTS | RSS

Jun 30, 2026 04:05 PM Form 8-K Aptevo Therapeutics Inc. For: Jun 29
Jun 30, 2026 08:06 AM Aptevo gets $1.5M grant to advance APVO451 cancer therapy
Jun 30, 2026 08:05 AM Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
Jun 22, 2026 12:11 PM Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: NIOWAVE, INC.
Jun 22, 2026 11:45 AM Form 3 Aptevo Therapeutics Inc. For: May 25 Filed by: NIOWAVE, INC.
May 28, 2026 08:03 PM Form 3 Aptevo Therapeutics Inc. For: May 20 Filed by: Janatpour Mary Jo
May 28, 2026 08:05 AM Aptevo Therapeutics names Mary Janatpour as chief scientific officer
May 28, 2026 08:05 AM Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
May 27, 2026 04:06 PM Form 8-K Aptevo Therapeutics Inc. For: May 25
May 27, 2026 08:05 AM Aptevo and Niowave form partnership for cancer drug development

Entities mentioned with APVO

View All Entities